



## Disposal of own shares

**Brussels (Belgium), 20 May 2022 – 20:00 (CEST) – Regulated information**

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following an exercise of stock options by a member of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant member of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
16 May 2022	15:25:11	Stock Option Plan 2019	400	€ 76,09

This press release is available on UCB SA/NV's website via the following [link](#).

---

### For further information, contact UCB:

#### Investor Relations

Antje Witte  
T +32 2 559 94 14  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

#### Corporate Communications

Laurent Schots  
T+32 2 559 92 64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

